Mark Glotkowski, PA
Physician Assistant · Ann Arbor, MINPI 1821398660
Payments from drug & device makers
Across 118 payments — averaging $80.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$8K
- Otsuka America Pharmaceutical, Inc.$537
- Alkermes, Inc.$315
- Johnson & Johnson$282
- Lundbeck LLC$272
- Indivior Inc.$181
- plus $394 from 8 others
What the payments were for
- Consulting fees$6,00063%
- Travel & lodging$8659%
- Food & beverage$2,53827%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 23 | $7,507 |
| Otsuka America Pharmaceutical, Inc. | 35 | $537 |
| Alkermes, Inc. | 6 | $315 |
| Johnson & Johnson | 10 | $282 |
| Lundbeck LLC | 15 | $272 |
| Indivior Inc. | 9 | $181 |
| Neurocrine Biosciences, Inc. | 8 | $157 |
| AbbVie | 3 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
| Corium, LLC | 2 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$880
- REXULTI$325
- INVEGA SUSTENNA$119
How this compares
$9,489 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 81 | $667,339 |
| Invega SustennaPaliperidone Palmitate | 146 | $400,663 |
| RexultiBrexpiprazole | 186 | $269,923 |
| VraylarCariprazine Hcl | 107 | $161,570 |
| AristadaAripiprazole Lauroxil | 28 | $61,860 |
| TrintellixVortioxetine Hydrobromide | 124 | $59,313 |
| Abilify MaintenaAripiprazole | 22 | $58,988 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $44,536 |
| GeodonZiprasidone Hcl | 12 | $42,719 |
| CaplytaLumateperone Tosylate | 19 | $37,215 |
| NuedextaDextromethorphan Hbr/Quinidine | 28 | $29,112 |
| VivitrolNaltrexone Microspheres | 17 | $27,954 |
| Fluphenazine Hcl | 119 | $22,455 |
| AuvelityDextromethorphan Hbr/Bupropion | 22 | $22,132 |
| Aripiprazole | 270 | $15,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $157 | $667,33981 claims |
| Johnson & JohnsonInvega Sustenna | $282 | $400,663146 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $537 | $328,911208 claims |
| AbbVieVraylar | $75 | $161,570107 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $315 | $134,35073 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $61 | $37,21519 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $12 | $29,11228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Ann Arbor
- Ashley AldridgeAnn Arbor$298K
- Thuy leAnn Arbor$38K
- Kaitlin BettensAnn Arbor$15K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.